Intravenous thrombolysis in unwitnessed stroke onset: MR WITNESS trial results.
Lee H SchwammOna WuShlee S SongLawrence L LatourAndria L FordAmie W HsiaAlona MuzikanskyRebecca A BetenskyAlbert J YooMichael H LevGregoire BoulouisArne LauerPedro CougoWilliam A CopenGordon J HarrisSteven J Warachnull nullPublished in: Annals of neurology (2018)
Intravenous thrombolysis within 4.5 hours of symptom discovery in patients with unwitnessed stroke selected by qDFM, who are beyond the recommended time windows, is safe. A randomized trial testing efficacy using qDFM appears feasible and is warranted in patients without large vessel occlusions. Ann Neurol 2018;83:980-993.
Keyphrases
- pulmonary embolism
- atrial fibrillation
- end stage renal disease
- high dose
- ejection fraction
- acute ischemic stroke
- newly diagnosed
- small molecule
- clinical trial
- magnetic resonance imaging
- prognostic factors
- study protocol
- high throughput
- patient reported outcomes
- computed tomography
- cerebral ischemia
- subarachnoid hemorrhage